Abstract
The role of hormone therapy as a neoadjuvant to radical prostate radiotherapy. Neoadjuvant hormone therapy may improve the therapeutic ratio of prostate radiotherapy in two ways: first, prostate shrinkage and the consequent reduction in target volume may reduce rectal toxicity, and so allow dose escalation; and second, hormone therapy may improve tumour control for a given radiation dose.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical oncology (Royal College of Radiologists (Great Britain))
Paper Title
Journal
Date
